Molina Healthcare

Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study

Retrieved on: 
Tuesday, March 19, 2024
Medicine, Cervical cancer, Patient, Cancer, HPV16, School, Congress, Gynaecology, Risk, Peking Union Medical College, Woman, LEEP, Safety, Gynecologic Oncology (journal), Pathology, Recurrence, Squamous intraepithelial lesion, Acceleration, Research, Șaeș, SGO, Death, National Cancer Center, Vaccination, Molina Healthcare, Annual general meeting, Health, Obstetrics, Hysterectomy, HSIL, Public health, Infection, Incidence, LSIL, HPV, Bleeding, Physician, Birth control

This study is a prospective, randomized, double-blinded, placebo-controlled multicenter Phase III global clinical study designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.

Key Points: 
  • This study is a prospective, randomized, double-blinded, placebo-controlled multicenter Phase III global clinical study designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.
  • Primary endpoint of the study is the proportion of responders at 6 months after the initial treatment.
  • The study is led by Dr. Jinghe Lang, an academician at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences.
  • Dr. Linda Wu, Chief Development Officer of Asieris Pharmaceuticals, said, "We are extremely proud of the results from the international multicenter Phase III clinical study of APL-1702.

San Diego Alzheimer's Partners Come Together

Retrieved on: 
Monday, March 18, 2024
Research, Partner, Aisén, Brain, MRI, Disease, CSF, SHARP, Diabetes, SAN, PET, Cerebrospinal fluid, Molina Healthcare, ACTC, Blood, Collection, Dementia, Amyloid, CBS 8

SAN DIEGO, March 18, 2024 /PRNewswire/ -- The Alzheimer's Therapeutic Research Institute (ATRI) and over a half-dozen of San Diego's Alzheimer's partners invite the community to a free event on March 23, 2024. A Day of SCervice, in support of accelerating Alzheimer's disease (AD) research through blood testing. Though the entire San Diego community is invited to visit ATRI and learn about new advances in AD research, those attending who are over the age of 55 and interested in participating in AD clinical trials can consent and, if eligible, have their blood drawn that day.

Key Points: 
  • SAN DIEGO, March 18, 2024 /PRNewswire/ -- The Alzheimer's Therapeutic Research Institute (ATRI) and over a half-dozen of San Diego's Alzheimer's partners invite the community to a free event on March 23, 2024.
  • Local CBS 8 news anchor and Alzheimer's San Diego Board Chair, Carlo Cecchetto, will moderate the morning panel.
  • "March 23 is also Day of SCervice, and the San Diego Trojan Family will be making a difference," said Shelley Moore, President-Elect of the San Diego Trojan League of San Diego County.
  • These clinical trials are vital to the work we do," said Janet Hamada-Kelley, Executive Director of the Alzheimer's Association San Diego & Imperial County an one of the event partners.

Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event

Retrieved on: 
Monday, March 11, 2024
SAN, Ulcerative colitis, Week, CDAI, IC50, Solipsism syndrome, Peripheral, Obesity, Cerebrospinal fluid, Cardiovascular disease, Treatment, MACE, NLRP3, Volunteering, Inflammation, Modulation, QD, Safety, Biomarker, UC, CAPS, Pharmacokinetics, Webcast, Patient, Molina Healthcare, TYK2, CSF, PIPE, Plasma, FCAS, Risk, Pharmaceutical industry

SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, will provide clinical and pipeline updates today during its virtual investor event.

Key Points: 
  • We believe these data support the potential for VTX3232 to emerge as a best-in-class CNS-penetrant NLRP3 inhibitor for the treatment of neuroinflammatory diseases.
  • We believe these data establish compelling clinical proof of concept for our peripheral NLRP3 inhibitor VTX2735.
  • At our virtual investor event, we will present data from the ongoing Phase 2 open-label extension.
  • Ventyx will host a virtual investor event today, Monday, March 11, 2024 from 11:00AM to 12:30PM ET.

Jhpiego pledges support to countries working to eliminate cervical cancer

Retrieved on: 
Wednesday, March 6, 2024
International, Cervical cancer, Research, Global Financing Facility, SUCCESS, World Bank, PAHO, International development, World Health Organization, Gavi, Pan American Health Organization, Molina Healthcare, UNICEF, HPV, Jhpiego, Bill, WHO, Vaccine

Baltimore, Md., March 06, 2024 (GLOBE NEWSWIRE) -- On the eve of International Women’s Day, Jhpiego joined a historic wave of commitments to ending cervical cancer as a public health problem as part of the global Cervical Cancer Elimination Initiative meeting in Cartagena de Indias, Colombia .

Key Points: 
  • Baltimore, Md., March 06, 2024 (GLOBE NEWSWIRE) -- On the eve of International Women’s Day, Jhpiego joined a historic wave of commitments to ending cervical cancer as a public health problem as part of the global Cervical Cancer Elimination Initiative meeting in Cartagena de Indias, Colombia .
  • Jhpiego is also committed in supporting at least five other countries for HPV vaccine coverage improvement and/or implementation of tailored interventions to increase HPV vaccine coverage.
  • Jhpiego has long been committed to integrated programs that link improved screening and treatment for cervical cancer as well as accelerating vaccine uptake.
  • We are inspired by these new commitments to work together across the whole spectrum of cervical cancer responses; together we have the potential to save many more women’s lives.”

Molina Healthcare Announces First Quarter 2024 Earnings Release and Conference Call Dates

Retrieved on: 
Wednesday, March 6, 2024
Managed Care, Health, Health Insurance, Molina Healthcare, Health care

Molina Healthcare, Inc. (NYSE: MOH) today announced details for the release of its results for the first quarter ending March 31, 2024.

Key Points: 
  • Molina Healthcare, Inc. (NYSE: MOH) today announced details for the release of its results for the first quarter ending March 31, 2024.
  • Molina Healthcare will issue its earnings release for the first quarter ending March 31, 2024, after the market closes on Wednesday, April 24, 2024, and will host a conference call and webcast to discuss the earnings release on Thursday, April 25, 2024, at 8:00 a.m. Eastern Time.
  • A telephonic replay of the conference call will be available through Thursday, May 9, 2024, by dialing (877) 344-7529 and entering the confirmation number, 7039934.
  • A live broadcast of Molina Healthcare’s conference call will be available on the Company’s website, molinahealthcare.com .

The MolinaCares Accord Provides Santee Sioux Nation $50,000 to Assist Members Following Tribal State of Emergency

Retrieved on: 
Wednesday, March 6, 2024
Philanthropy, Health, Consumer, Other Philanthropy, Other Health, Foundation, General Health, Propane, Santee Sioux Reservation, Tribe, Medicaid, Weather, Molina Healthcare, Food

The Molina Cares Accord (“MolinaCares”), in collaboration with Molina Healthcare of Nebraska (“Molina”), provided a grant to support the Santee Sioux Nation ’s efforts to provide food and heat in the wake of a winter storm.

Key Points: 
  • The Molina Cares Accord (“MolinaCares”), in collaboration with Molina Healthcare of Nebraska (“Molina”), provided a grant to support the Santee Sioux Nation ’s efforts to provide food and heat in the wake of a winter storm.
  • The $50,000 donation will help purchase propane and food, both of which are not readily accessible on the reservation when storms hit.
  • In January, the Santee Sioux Nation declared a Tribal State of Emergency.
  • “We are proud to support the Santee Sioux Nation by helping to supply necessities for its members,” said Frank Clepper, plan president for Molina Healthcare of Nebraska.

The MolinaCares Accord Donates $100,000 to Support Kansas Nonprofits

Retrieved on: 
Tuesday, March 5, 2024
General Health, Fund Raising, Health, Foundation, Philanthropy, Catholic Church, Hospital, Caregiver, Education, El Centro, California, Parent, Food, Homelessness, Accord, Organization, Mother, Housing, Molina Healthcare, Nursing

The MolinaCares Accord (“MolinaCares”) has committed $100,000 to nonprofits across Kansas to address social determinants of health and reduce health disparities in underserved communities.

Key Points: 
  • The MolinaCares Accord (“MolinaCares”) has committed $100,000 to nonprofits across Kansas to address social determinants of health and reduce health disparities in underserved communities.
  • “MolinaCares is committed to improving the health and well-being of communities across Kansas and we are proud to team up with organizations that share this vision,” said Aaron Dunkel, plan president of Molina Healthcare of Kansas.
  • Funds will support the P-CAP program, which provides intensive in-home support for mothers with substance-use disorders.
  • “We are grateful to MolinaCares for its generous donation,” said Monica Murnan, director of community support services of Greenbush Center.

Drug Abuse Testing Market, Size, Global Forecast Report 2024-2030: Focus on Alcohol, Cannabis/Marijuana, Cocaine, Opioids, Amphetamine & Methamphetamine, and LSD - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 5, 2024
Medical Devices, Hemp, Cannabis, Health Technology, Other Health, General Health, Pharmaceutical, Health, Agriculture, Natural Resources, Collection, Molina Healthcare, Breathalyzer, Urine, Cocaine, Education, Prohibition, Substance abuse, Health Promotion International, Abuse, Government, Sport, Urinalysis, Saliva, Illegal drug trade, Organization, Psychological abuse, Drug overdose, CDC, Mortality, Ageing, Laboratory, Research, Drug

Drug of Abuse Testing Market size is expected to hit US$ 10.28 Billion by 2030 from US$ 6.18 Billion in 2023.

Key Points: 
  • Drug of Abuse Testing Market size is expected to hit US$ 10.28 Billion by 2030 from US$ 6.18 Billion in 2023.
  • Innovations in technology are continuously emerging to expedite and enhance drug testing efficiency in response to the growing demand for such services.
  • The drug abuse testing market is generally pushed by strict laws that mandate drug abuse testing, growing government initiatives concerning drug abuse, rising consumption of alcohol and different drugs, and growing mortality because of drugs.
  • The growing global population engaged in alcohol and illicit drug use, encompassing substances like marijuana and cocaine, drives the drug abuse testing market's growth.

Toyoda Gosei Invests in Craif, Inc., a Startup Developing Urine Test Kits for Higher Possibility of the Early Detection of Cancer

Retrieved on: 
Tuesday, March 5, 2024
Professional Services, Oncology, Start-Up, General Automotive, Aftermarket, Medical Devices, Automotive, Biotechnology, Automotive Manufacturing, Medical Supplies, Manufacturing, Health, Nagoya University, Multimedia, AI, Molina Healthcare, Investment, MicroRNA, Gosei, Urine, Longevity, Cancer

Toyoda Gosei Co., Ltd. (TOKYO:7282), in its efforts to pioneer new businesses to resolve societal healthcare issues, has invested1 in Craif, Inc., a startup out of Nagoya University that develops urine test kits that enhance the possibility of the early detection of cancer.

Key Points: 
  • Toyoda Gosei Co., Ltd. (TOKYO:7282), in its efforts to pioneer new businesses to resolve societal healthcare issues, has invested1 in Craif, Inc., a startup out of Nagoya University that develops urine test kits that enhance the possibility of the early detection of cancer.
  • These kits comprehensively and efficiently capture and measure small microRNA molecules called miRNA2 in urine, which are generally difficult to detect.
  • 1 Investment made in February 2024, through Toyoda Gosei’s Corporate Venture Capital Dept., an internal organization dedicated to these investments.
  • 2 The amount and type of miRNA contained in urine differs depending on the type of cancer and its progression.

Molina Healthcare Provides Update on the Virginia Cardinal Care Managed Care Contract

Retrieved on: 
Thursday, February 29, 2024
Health, Professional Services, Insurance, Managed Care, Health Insurance, Health care, Molina Healthcare, Commonwealth

Molina Healthcare, Inc. (NYSE: MOH) (“Molina” or the “Company”) announced today that its Virginia health plan subsidiary, Molina Healthcare of Virginia, was not selected as an awardee in the Commonwealth of Virginia’s Cardinal Care Managed Care program.

Key Points: 
  • Molina Healthcare, Inc. (NYSE: MOH) (“Molina” or the “Company”) announced today that its Virginia health plan subsidiary, Molina Healthcare of Virginia, was not selected as an awardee in the Commonwealth of Virginia’s Cardinal Care Managed Care program.
  • The current contract is expected to continue into the summer of 2024.
  • Molina Healthcare of Virginia currently serves approximately 140,000 members.
  • The Company will evaluate next steps as further information becomes available.